{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:55:48Z","timestamp":1781639748180,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["PIP-0044-2020"],"award-info":[{"award-number":["PIP-0044-2020"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["RB-0003-2019 ; RC-0004-2020"],"award-info":[{"award-number":["RB-0003-2019 ; RC-0004-2020"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pathological complete response (pCR) after neoadjuvant therapy is a robust surrogate marker for long-term outcomes in breast cancer. Despite major advances with targeted therapies, a significant proportion of patients fail to achieve pCR, underscoring the urgent need for reliable biomarkers that can predict treatment response and guide patient stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a two-phase study including 53 patients with HER2-positive, hormone receptor\u2013negative breast cancer treated with neoadjuvant chemotherapy plus anti-HER2 agents. Transcriptomic profiling (discovery cohort,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913) identified differentially expressed genes associated with therapeutic response, which were validated by qPCR in an independent cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940). Functional enrichment analysis was performed to explore the biological pathways underlying the differential response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Differential expression analysis revealed 6251 genes associated with response, with significant enrichment in xenobiotic metabolism and steroid hormone biosynthesis pathways. Within these, members of the UGT2B family (UGT2B10, UGT2B17, UGT2B28) were overexpressed in non-responders. Validation confirmed UGT2B17 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023, AUC\u2009=\u20090.699, sensitivity 77.2%, specificity 64.5%) and UGT2B28 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046, AUC\u2009=\u20090.677) as predictive biomarkers of resistance to neoadjuvant therapy. UGT2B17 showing the highest discriminative value.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>UGT2B17 overexpression is associated with resistance to neoadjuvant therapy in HER2-positive breast cancer, supporting its potential role as a predictive biomarker. Integration of UGT2B17 into molecular panels could improve patient stratification and guide personalized therapeutic strategies in this subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12282-026-01840-9","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:03:26Z","timestamp":1772802206000},"page":"634-643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["UGT2B17 as a predictive biomarker of complete pathological response in HER2\u2009+\u2009breast cancer"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9011-0446","authenticated-orcid":false,"given":"Ana","family":"Gil-Torralvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. \u00c1ngeles","family":"Dom\u00ednguez-Cejudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5726-2453","authenticated-orcid":false,"given":"Sonia","family":"Molina-Pinelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1853-1822","authenticated-orcid":false,"given":"Carmen","family":"Garrig\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1268-4588","authenticated-orcid":false,"given":"Marta","family":"Benavent-Vi\u00f1uales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-5877","authenticated-orcid":false,"given":"Alejandro","family":"Falc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3894-0765","authenticated-orcid":false,"given":"M\u00f3nica","family":"Cejuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rodr\u00edguez-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-2782","authenticated-orcid":false,"given":"Javier","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1181-5622","authenticated-orcid":false,"given":"Manuel","family":"Ru\u00edz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Salvador-Bofill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"1840_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet"},{"key":"1840_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273\u201383.","journal-title":"N Engl J Med"},{"key":"1840_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Kim SB, Cort\u00e9s J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461\u201371.","journal-title":"Lancet Oncol"},{"key":"1840_CR4","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Von Minckwitz","year":"2012","unstructured":"Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796\u2013804.","journal-title":"J Clin Oncol"},{"key":"1840_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17:791\u2013800.","journal-title":"Lancet Oncol"},{"key":"1840_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109\u201319.","journal-title":"N Engl J Med"},{"key":"1840_CR7","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","volume":"24","author":"A Prat","year":"2015","unstructured":"Prat A, Pineda E, Adamo B, Galv\u00e1n P, Fern\u00e1ndez A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24:S26\u201335.","journal-title":"Breast"},{"key":"1840_CR8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andr\u00e9 F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275\u201381.","journal-title":"J Clin Oncol"},{"key":"1840_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/jmg.39.8.608","volume":"39","author":"PO Chappuis","year":"2002","unstructured":"Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, et al. A significant response to neoadjuvant chemotherapy in BRCA1\/2 related breast cancer. J Med Genet. 2002;39:608\u201310.","journal-title":"J Med Genet"},{"key":"1840_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(11)70231-5","volume":"12","author":"A Di Leo","year":"2011","unstructured":"Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 2011;12:1134\u201342.","journal-title":"Lancet Oncol"},{"key":"1840_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/clpt.2014.126","volume":"96","author":"C Guillemette","year":"2014","unstructured":"Guillemette C, L\u00e9vesque \u00c9, Rouleau M. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin Pharmacol Ther. 2014;96:324\u201339.","journal-title":"Clin Pharmacol Ther"},{"key":"1840_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41523-023-00572-9","volume":"9","author":"N Cosgrove","year":"2023","unstructured":"Cosgrove N, Eustace AJ, O\u2019Donovan P, et al. Predictive modelling of response to neoadjuvant therapy in HER2\u2009+\u2009breast cancer. npj Breast Cancer. 2023;9:72.","journal-title":"npj Breast Cancer"},{"key":"1840_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41416-019-0722-0","volume":"122","author":"EP Allain","year":"2020","unstructured":"Allain EP, Rouleau M, L\u00e9vesque E, Guillemette C. Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression. Br J Cancer. 2020;122:1277\u201387.","journal-title":"Br J Cancer"},{"key":"1840_CR14","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2012-08-447359","volume":"121","author":"M Gruber","year":"2013","unstructured":"Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, et al. Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood. 2013;121:1175\u201383.","journal-title":"Blood"},{"key":"1840_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.eururo.2015.06.054","volume":"69","author":"A Belledant","year":"2016","unstructured":"Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, et al. The UGT2B28 sex-steroid inactivation pathway is a regulator of steroidogenesis and modifies the risk of prostate cancer progression. Eur Urol. 2016;69:601\u20139.","journal-title":"Eur Urol"},{"key":"1840_CR16","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.1158\/0008-5472.CAN-15-3372","volume":"76","author":"DG Hu","year":"2016","unstructured":"Hu DG, Selth LA, Tarulli GA, Meech R, Wijayakumara D, Chanawong A, et al. Androgen and estrogen receptors in breast cancer coregulate human UDP-glucuronosyltransferases 2B15 and 2B17. Cancer Res. 2016;76:5881\u201393.","journal-title":"Cancer Res"},{"key":"1840_CR17","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2022","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022."},{"key":"1840_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2009\u2013 \u2206\u2206CT method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"1840_CR19","doi-asserted-by":"publisher","first-page":"12869","DOI":"10.1038\/s41598-023-40071-2","volume":"13","author":"S Orr\u00f9","year":"2023","unstructured":"Orr\u00f9 S, Pascariello E, Pes B, Rallo V, Barbara R, Muntoni M, et al. Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype. Sci Rep. 2023;13:12869.","journal-title":"Sci Rep"},{"key":"1840_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13058-024-01813-w","volume":"26","author":"N Zhang","year":"2024","unstructured":"Zhang N, Huang Y, Wang G, Xiang Y, Jing Z, Zeng J, et al. Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2\u2009+\u2009breast cancer. Breast Cancer Res. 2024;26:64.","journal-title":"Breast Cancer Res"},{"key":"1840_CR21","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.3390\/cancers12123564","volume":"12","author":"W Liu","year":"2020","unstructured":"Liu W. Steroid hormone metabolism and resistance mechanisms in breast cancer: implications of UGT2B enzymes. Cancers (Basel). 2020;12:3564.","journal-title":"Cancers (Basel)"},{"key":"1840_CR22","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1152\/physrev.00058.2017","volume":"99","author":"R Meech","year":"2019","unstructured":"Meech R, Hu DG, McKinnon RA, Mubarokah SN, Haines AZ, Nair PC, et al. The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms. Physiol Rev. 2019;99:1153\u2013222.","journal-title":"Physiol Rev"},{"key":"1840_CR23","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-14-1370","volume":"21","author":"HA Zahreddine","year":"2015","unstructured":"Zahreddine HA, Borden KL. Molecular pathways: GLI1-induced drug glucuronidation in resistant cancer cells. Clin Cancer Res. 2015;21:2207\u201310.","journal-title":"Clin Cancer Res"},{"key":"1840_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.pharmthera.2016.01.009","volume":"159","author":"Z Mazerska","year":"2016","unstructured":"Mazerska Z, Mr\u00f3z A, Paw\u0142owska M, Augustin E. The role of glucuronidation in drug resistance. Pharmacol Ther. 2016;159:35\u201355.","journal-title":"Pharmacol Ther"},{"key":"1840_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/03602532.2022.2083632","volume":"54","author":"D Dimunov\u00e1","year":"2022","unstructured":"Dimunov\u00e1 D, Matou\u0161kov\u00e1 P, Podlipn\u00e1 R, Bou\u0161ov\u00e1 I, Sk\u00e1lov\u00e1 L. The role of UDP-glycosyltransferases in xenobiotic resistance. Drug Metab Rev. 2022;54:282\u201398.","journal-title":"Drug Metab Rev"},{"key":"1840_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1021\/acs.jcim.3c01514","volume":"64","author":"D Ahire","year":"2024","unstructured":"Ahire D, Mariasoosai C, Naji-Talakar S, Natesan S, Prasad B. Promiscuity and quantitative contribution of UGT2B17 in drug and steroid metabolism determined by experimental and computational approaches. J Chem Inf Model. 2024;64:483\u201398.","journal-title":"J Chem Inf Model"},{"key":"1840_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bcp.2018.08.003","volume":"156","author":"H Zhang","year":"2018","unstructured":"Zhang H, Basit A, Busch D, Yabut K, Bhatt DK, Drozdzik M, et al. Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism. Biochem Pharmacol. 2018;156:32\u201342.","journal-title":"Biochem Pharmacol"},{"key":"1840_CR28","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1124\/dmd.118.080952","volume":"46","author":"DK Bhatt","year":"2018","unstructured":"Bhatt DK, Basit A, Zhang H, Gaedigk A, Lee SB, Claw KG, et al. Hepatic abundance and activity of androgen- and drug-metabolizing enzyme UGT2B17 are associated with genotype, age, and sex. Drug Metab Dispos. 2018;46:888\u201396.","journal-title":"Drug Metab Dispos"},{"key":"1840_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21:440\u20136.","journal-title":"Pharmacogenet Genomics"},{"key":"1840_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3109\/03602532.2015.1131292","volume":"48","author":"DG Hu","year":"2016","unstructured":"Hu DG, Mackenzie PI, McKinnon RA, Meech R. Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk. Drug Metab Rev. 2016;48:47\u201369.","journal-title":"Drug Metab Rev"},{"key":"1840_CR31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1124\/dmd.119.086330","volume":"47","author":"JP \u00c9mond","year":"2019","unstructured":"\u00c9mond JP, Labriet A, Desjardins S, Rouleau M, Villeneuve L, Hovington H, et al. Factors affecting interindividual variability of hepatic UGT2B17 protein expression examined using a novel specific monoclonal antibody. Drug Metab Dispos. 2019;47:444\u201352.","journal-title":"Drug Metab Dispos"},{"key":"1840_CR32","doi-asserted-by":"publisher","first-page":"1088458","DOI":"10.3389\/fonc.2022.1088458","volume":"12","author":"W Liu","year":"2022","unstructured":"Liu W, Li J, Zhao R, Lu Y, Huang P. The uridine diphosphate (UDP)-glycosyltransferases (UGTs) superfamily: the role in tumor cell metabolism. Front Oncol. 2022;12:1088458.","journal-title":"Front Oncol"},{"key":"1840_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41416-022-02040-w","volume":"128","author":"M Rouleau","year":"2023","unstructured":"Rouleau M, Van Long FN, Turcotte V, Caron P, Lacombe L, Aprikian A, et al. Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer. Br J Cancer. 2023;128:285\u201396.","journal-title":"Br J Cancer"},{"key":"1840_CR34","first-page":"27","volume":"66","author":"LB Farrar","year":"2006","unstructured":"Farrar LB, Karimi Kinyamu H, Flintosh N, Archer TK, Grant DJ. The regulation of the UDP-glucuronosyltransferase 2B28 gene by glucocorticoids and epidermal growth factor. Cancer Res. 2006;66:27.","journal-title":"Cancer Res"},{"issue":"6","key":"1840_CR35","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/j.clbc.2022.04.002","volume":"22","author":"RS Vanguri","year":"2022","unstructured":"Vanguri RS, Finkle JD, Bean GR, et al. Tumor immune microenvironment and response to neoadjuvant chemotherapy in hormone receptor\/HER2\u2009+\u2009early stage breast cancer. Clin Breast Cancer. 2022;22(6):e808\u201318.","journal-title":"Clin Breast Cancer"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01840-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01840-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01840-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:30:17Z","timestamp":1781638217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01840-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1840"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01840-9","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.G., M.B-V., A.F., M.C., B.R-A., J.P., M.R-B., and J.S-B. have received honoraria, travel support and\/or consulting fees from pharmaceutical companies involved in breast cancer therapeutics, including Roche, Pfizer, Novartis, AstraZeneca and Daiichi-Sankyo. These activities are unrelated to the present work. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Research Ethics Committee of the Virgen del Roc\u00edo Hospital (reference number 0920-N20) and was carried out in compliance with the principles of the Declaration of Helsinki and its amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants were informed about the objectives and procedures of the study and gave their informed consent in writing, and confidentiality and proper handling of personal data were guaranteed in all phases of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}